License to Licensed Technology Sample Clauses

License to Licensed Technology. Except as otherwise hereinafter provided, subject to Government Regulations and the provisions of this Agreement, LTC hereby grants to Licensee a sole and exclusive license to use the Licensed Technology to make, use, sell and offer for sale Polymer Materials and Products in the Territory.
Sample 1
AutoNDA by SimpleDocs
License to Licensed Technology. Subject to Government Regulations and the provisions of this Agreement, LTC hereby grants to Licensee a perpetual license to use the Licensed Technology solely for the manufacture of CRA Materials in Japan, and the sale of CRA Materials:
Sample 1
License to Licensed Technology. Subject to Government Regulations and the provisions of this Agreement, LTC hereby grants to Licensee a perpetual license to use the Licensed Technology in Territory B solely for the manufacture of CRA Materials in Territory B and the sale of CRA Materials:
Sample 1
License to Licensed Technology. Subject to the terms and conditions of this Agreement, NXP SOFTWARE hereby grants to LBT, and LBT hereby accepts from NXP SOFTWARE, a non-exclusive, personal, non-transferable worldwide copyright license, without the right to sublicense, to:
Sample 1
License to Licensed Technology. (a) As of the Closing Date, Vitesse hereby grants to Buyer a worldwide, personal, non-exclusive, royalty-free, paid-up, nontransferable (except as set forth in Section 4.2 and Section 9.3), irrevocable (except as set forth in Section 7) license to make, have made, use, offer to sell, sell, have sold, import, duplicate, create derivative works and Improvements based upon, distribute, have distributed, and otherwise exploit for any purpose the Licensed Technology solely: (i) as embodied or incorporated in products, and (ii) in connection with services that incorporate, embody or otherwise practice the Licensed Technology;, subject in either case during the Restricted Period to the License Restrictions set forth below. Notwithstanding the foregoing, during the Restricted Period (and, with respect to the ‘213 Patent Family, until the expiration of the term of the last-to-expire Patent in the ‘213 Patent Family), Buyer will only have a license to make, have made, use, offer to sell, sell, have sold, import, duplicate, create derivative works and Improvements based upon, distribute, have distributed, or otherwise exploit the Licensed Technology: (i) in connection with Serial Attached SCSI (SAS), Serial ATA (SATA), PCI Express, PCEe, and PCI-e protocols, but only within products deployed within the Storage Market; and (ii) in connection with Hyper-Transport and Infiniband protocols, but only within expander products deployed within the Storage Market (the foregoing clauses (i) – (ii), the “License Restrictions”). For avoidance of doubt, during the Restricted Period, the License Restrictions mean that Buyer has no license under this Agreement to make, have made, use, offer to sell, sell, have sold, import, duplicate, create derivative works and Improvements based upon, distribute, have distributed, or otherwise exploit any product incorporating the Licensed Technology and containing Gigabit Ethernet (GbE), 10 Gigabit Ethernet (10GbE), 40 Gigabit Ethernet, 100 Gigabit Ethernet, Fibre Channel or SONET protocols. No sooner than ninety (90) days prior to the end of the Restricted Period, Buyer may give notice to Vitesse that Buyer desires to license the ‘213 Patent Family free of any License Restrictions and the parties will, within thirty (30) days of Vitesse’s receipt of such notice, begin good faith negotiations with respect to whether Vitesse and Buyer will enter into such a license which will include, but not be limited to, license fees and royalties to be paid t...
Sample 1
License to Licensed Technology 
Sample 1Sample 2

Related to License to Licensed Technology

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Licensed Patents Immune Design, at its expense, shall have the first right to file, prosecute and maintain all Licensed Patents for which Immune Design has any exclusive rights under this Agreement using patent counsel reasonably approved by IDRI, including conducting any interferences, reexaminations, reissues, oppositions, or request for patent term extension relating thereto. Immune Design shall conduct such filing, prosecution and maintenance in good faith, taking into consideration IDRI’s retained rights hereunder, and consistent with reasonable business judgment, provide IDRI with all relevant or material documentation and proposed filing in the Territory so that IDRI may be concurrently and promptly informed of the continuing prosecution, and consult with IDRI with regards to Immune Design’s patent strategy with the Licensed Patents for which Immune Design has any exclusive rights under this Agreement. Licensed Patents in the name of IDRI shall remain in the name of IDRI. Immune Design shall use commercially reasonable efforts to ***, as applicable. To the extent such ***, Immune Design shall provide IDRI reasonable opportunity to review and comment on such prosecution efforts regarding such Licensed Patents in the Territory, and any IDRI comments will be reasonably considered in such prosecution efforts, and included to the extent affecting the IDRI Exclusive Field or IDRI Territory, as the case may be. If Immune Design determines in its sole discretion to abandon or not maintain any Licensed Patent for which Immune Design has any exclusive rights under this Agreement in the Territory, then Immune Design shall promptly provide IDRI with written notice of such determination at least sixty (60) days before any deadline for taking action to avoid abandonment and shall provide IDRI with the right, opportunity and reasonable assistance to prepare, file, prosecute and maintain such Licensed Patent in the applicable jurisdiction in IDRI’s sole discretion and at IDRI’s expense, provided that Immune Design shall provide such reasonable assistance at its *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. own costs and expenses. If IDRI elects to prepare, file, prosecute and maintain such Licensed Patent in such jurisdiction for which Immune Design has any exclusive rights, then Immune Design’s license rights to such Licensed Patent in such country will become nonexclusive in such country under such Licensed Patent (and/or patent application). If IDRI desires Immune Design to file, in a particular jurisdiction, a Licensed Patent for which Immune Design has any exclusive rights under this Agreement that claims priority to another Licensed Patent for which Immune Design has any exclusive rights under this Agreement, IDRI shall provide written notice to Immune Design requesting that Immune Design file such patent application in such jurisdiction. If IDRI provides such written notice to Immune Design, Immune Design shall either (i) file and prosecute such patent application and maintain any patent issuing thereon in such jurisdiction and the Parties shall share the related costs and expenses (A) in countries *** on the basis of *** percent (***%) Immune Design: *** percent (***%) IDRI or (B) in countries within the IDRI Territory equally; or (ii) notify IDRI that Immune Design does not desire to file such patent application in such jurisdiction and provide IDRI with the opportunity to file and prosecute such patent application, provided that if IDRI files and prosecutes such patent application in such jurisdiction, then Immune Design’s license rights to such License Patent in such country will become nonexclusive in such country under such Licensed GLA Patent (and/or patent application). Immune Design shall be responsible for the costs and expenses incurred in connection with its own activities for filing, prosecuting and maintaining the Licensed Patents; IDRI shall be responsible for monitoring of such activities by IDRI.

  • Licensed Patent Rights The term “Licensed Patent Rights” shall mean rights arising out of or resulting from:

  • Research License Following Selection of each CGI Antigen (or exercise of a Buy-In Right for each CGI Antigen) and subject to the terms and conditions of this Agreement, ABX agrees to grant, and hereby grants, to CGI a nonexclusive sublicense under the Licensed Technology to develop, make, have made, use, import or export or otherwise transfer physical possession of (but not to sell, lease, offer to sell or lease, or otherwise transfer title to) Covered Products related to such CGI Antigen and cells that express or secrete Antibodies to such CGI Antigen, in each case solely for purposes relating to or in connection with research or development (i) of Covered Products for use in the field of Gene Therapy or (ii) involving Genetic Material when used with viral or nonviral gene transfer systems. CGI shall have the right to sublicense the rights granted under this Section 2.5 upon the approval of ABX, which approval shall not be unreasonably withheld. In the event that ABX refuses to approve such a sublicense, ABX shall, to the extent that ABX has the right to do so, grant at CGI's request a nonexclusive sublicense of such rights directly to a non-Affiliate third party designated by CGI on terms and conditions substantially identical to the applicable terms and conditions of this Agreement. The sublicense granted by ABX under this Section 2.5 with respect to a CGI Antigen (and the further sublicenses, if any, granted by CGI under this Section 2.5 with respect to such CGI Antigen) shall terminate at such time as (A) CGI sends ABX an Abandonment Notice pursuant to Section 2.4.1 above regarding such CGI Antigen or (B) CGI enters into a CGI Product Sublicense related to such CGI Antigen; provided, however, that termination of a sublicense under this Section 2.5 with respect to a CGI Antigen pursuant to (B) above shall not affect the duration or survival of a grant of similar rights or sublicense under the CGI Product Sublicense with respect to such CGI Antigen, which rights or sublicense shall terminate or expire only in accordance with the terms of such CGI Product Sublicense. In the event that ABX enters into a Product Sublicense with respect to a CGI Antigen and CGI has not within six (6) months thereafter entered into a CGI Product Sublicense with respect to such CGI Antigen, the sublicense granted under this Section 2.5 with respect to such CGI Antigen shall terminate. It is understood and agreed that (x) as to ABX-Controlled Rights, the grant of rights under this Section 2.5 shall be subject to and limited in all respects by the terms of the applicable ABX In-License(s) pursuant to which such ABX-Controlled Rights were granted to ABX and (y) the rights and sublicenses granted to CGI under this Section 2.5 or any other provision of this Agreement shall be subject in all respects to the GenPharm Cross License.

  • Third Party Technology The assignment of any applicable license agreements with respect to Third Party Technology are set forth in the General Assignment and Assumption Agreement.

  • Patent Rights The term “

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

  • Licensed Intellectual Property Section 3.17(h)(vi)...................................29

  • Licensed Software Section 3.17(f).......................................27

  • Grant of License to Use Intellectual Property For the purpose of enabling the Collateral Agent to exercise rights and remedies under this Article at such time as the Collateral Agent shall be lawfully entitled to exercise such rights and remedies, each Grantor hereby grants to the Collateral Agent an irrevocable, non-exclusive license (exercisable without payment of royalty or other compensation to the Grantors) to use, license or sub-license any of the Collateral consisting of Intellectual Property now owned or hereafter acquired by such Grantor, and wherever the same may be located, and including in such license reasonable access to all media in which any of the licensed items may be recorded or stored and to all computer software and programs used for the compilation or printout thereof. The use of such license by the Collateral Agent shall be exercised, at the option of the Collateral Agent, upon the occurrence and during the continuation of an Event of Default; provided that any license, sub-license or other transaction entered into by the Collateral Agent in accordance herewith shall be binding upon the Grantors notwithstanding any subsequent cure of an Event of Default.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!